- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01045369
A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects (KALYINTE)
April 27, 2017 updated by: Joseph Gathe Jr. M.D., Therapeutic Concepts
A Phase IV 48 Week, Open Label, Pilot Study of Kaletra and Intelence Tablets in Naive Subjects
The purpose of this study is to see if using a combination of other drug classes, like the ones that Kaletra® and Intelence™ belong to, can still help reduce the amount of HIV in your blood.
Using Kaletra® and Intelence™ without other drugs is not approved by the FDA and so their use in this study is experimental.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77004
- Therapeutic Concepts, PA
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- HIV-1 RNA ≥ 5000 copies/mL by Roche Amplicor 1.5v Primer
- More than 18 years of age
- Provide written informed consent and willingness to participate in and comply
- Less than 7 days of prior ART with any licensed or investigational compound
- Does not currently have or has not been treated for an active opportunistic infection (OI) within 30 days of screening
- Vital signs, physical examination and laboratory results do not exhibit evidence of acute illness
- A female who is a non-childbearing potentiator or if in child-bearing potential, has a negative serum pregnancy test at screen and agrees to one of the following: complete abstinence from intercourse from 2 weeks prior to administration of the study drug, throughout the study, and for at least 2 weeks after completion or premature discontinuation from the study to account for elimination of the investigational drug. Should a patient decide to become sexually active during the course of the study, she must be counseled and be willing to use one of the birth control methods like double barrier method, intrauterine device, sterilization and any other methods.
NOTE: Data are insufficient to exclude a clinically important interaction of LPV/r with drugs, such as hormonal contraceptives, that are highly metabolized by the cytochrome P450 enzyme system. As a result, hormonal contraception is not considered adequate.
Exclusion Criteria:
- Patient with active AIDS-defining opportunistic infection in the 30 days prior to baseline and that, in the opinion of the investigator, would preclude the patient from participating in the study (See Appendix C).
- Patient has a weighted genotypic score for etravirine ≥3 . (See Appendix D)
- Patient has >3 mutations at 10, 20, 24, 32, 33, 36, 46, 47, 48, 50, 54, 73, 82, 84, or 90 in protease or ≥1 of the following mutations in protease (I47A/V, V32I, or L76V).
- History of active substance abuse.
- Pregnant at time of screening evaluation or breast-feeding.
- Patient, in the opinion of the investigator, is unlikely to be able to complete the 48-week dosing period and protocol evaluations and assessments or adhere to the study drug regimen.
- Serious medical condition, such as diabetes, congestive heart failure, cardiomyopathy or other cardiac dysfunction, which in the opinion of the investigator would compromise the safety of the patient
- Malabsorption syndrome or other gastrointestinal dysfunction, which may interfere with drug absorption or render the patient unable to take oral medication.
- Undergoing interferon therapy for HCV or anticipates undergoing therapy during the course of this trial
- HBV co-infection
Laboratory results within 30 days prior to the first dose of study medication:
- Hemoglobin concentration < 8.0 g/dL
- Absolute neutrophil count < 750 cells/mm3
- Platelet count <50,000 cells/ mm3
- Aminotransferase (AST, ALT) >3 times ULN
- Serum creatinine >1.5 times the Upper Limits of Normal (ULN)
- Radiation therapy or cytotoxic chemotherapeutic agents within 4 weeks prior to entry, or has an anticipated need for these agents within the study period.
- Immunomodulating agents, such as systemic corticosteroids, interleukins, or interferon's within 4 weeks prior to study entry, or patients who have received an HIV immunotherapeutic vaccine within 3 months prior to entry. Asthmatic patients using inhaled corticosteroids are eligible for enrollment.
- Methadone therapy
- Foscarnet therapy or therapy with other agents with documented activity against HIV-1 in vitro.
- Taking astemizole, terfenadine, cisapride, oral midazolam, triazolam, flecainide, pimozide, propafenone, St. John's Wort, lovastatin, simvastatin, and rifampin or ergot derivatives.
- Allergy to any of the study drugs or any excipients therein.
- Patient requires inhaled or intranasal fluticasone.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Kaletra And Intelence
This is a Phase IV, 48-week, open-label, pilot study in 30 ARV-naïve patients examining the safety, viral response, and tolerability of Kaletra® and Intelence™ tablets.
|
Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients with plasma HIV-1 RNA < 400 copies/mL at weeks 24 and 48
Time Frame: At weeks 24 and 48
|
At weeks 24 and 48
|
Proportion of patients with plasma HIV-1 RNA < 75 copies/mL at weeks 24 and 48
Time Frame: At weeks 24 and 48
|
At weeks 24 and 48
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients with plasma HIV-1 RNA < 400 copies/mL or < 75 copies/mL at each study visit
Time Frame: At weeks 24 and 48
|
At weeks 24 and 48
|
Number of weeks until HIV RNA < 400 copies/mL and < 75 copies/mL, respectively
Time Frame: At weeks 24 and 48
|
At weeks 24 and 48
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Joseph C. Gathe, Jr., MD, Therapeutic Concepts
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (ACTUAL)
April 1, 2011
Study Completion (ACTUAL)
June 1, 2011
Study Registration Dates
First Submitted
January 8, 2010
First Submitted That Met QC Criteria
January 8, 2010
First Posted (ESTIMATE)
January 11, 2010
Study Record Updates
Last Update Posted (ACTUAL)
May 1, 2017
Last Update Submitted That Met QC Criteria
April 27, 2017
Last Verified
January 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Etravirine
Other Study ID Numbers
- 101-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
Clinical Trials on Kaletra and Intelence Tablets
-
Ottawa Hospital Research InstituteAbbottCompleted
-
AIDS Arms Inc.CompletedHIV-1 | AIDSUnited States
-
Fundacion SEIMC-GESIDAAbbottCompletedHIV Infections | HIV InfectionSpain
-
PENTA FoundationMedical Research Council; ANRS, Emerging Infectious DiseasesCompletedAntiretroviral Therapy in HIV-1 Infected ChildrenNetherlands, Germany, United Kingdom, Ireland, Thailand
-
The HIV Netherlands Australia Thailand Research...Chulalongkorn University; Queen Sirikit National Institute of Child Health; Srinagarind... and other collaboratorsCompletedHIV-infected ChildrenThailand
-
Therapeutic ConceptsCompleted
-
University of Wisconsin, MadisonCompleted
-
Eunice Kennedy Shriver National Institute of Child...American Association of Colleges of PharmacyCompleted
-
GlaxoSmithKlineCompleted